Literature DB >> 2410282

Central and peripheral sites for cardiovascular actions of dynorphin-(1-13) in rats.

B Gautret, H Schmitt.   

Abstract

Dynorphin-(1-13) (i.v.) induced bradycardia and hypotension in artificially ventilated anaesthetized rats. These effects were prevented by MRZ 2266 BS. The bradycardia was inhibited by bilateral vagotomy whereas the fall in blood pressure was not sensitive to bilateral vagotomy and chlorpheniramine treatment. In pithed rats, dynorphin-(1-13) reduced heart rate. This bradycardia was prevented by MRZ 2266 BS but not by tertatolol and cimetidine. It is suggested that the dynorphin-(1-13)-induced effects result from the stimulation of central and cardiac kappa-opiate receptors.

Entities:  

Mesh:

Substances:

Year:  1985        PMID: 2410282     DOI: 10.1016/0014-2999(85)90766-6

Source DB:  PubMed          Journal:  Eur J Pharmacol        ISSN: 0014-2999            Impact factor:   4.432


  4 in total

1.  Effect of dynorphin A(1-13) on cardiomyocytes in culture: modulation of the response to increased extracellular calcium, but no effect on intrinsic cardiac contractile frequency or the response to isoproterenol or increased extracellular potassium.

Authors:  S W Rabkin
Journal:  Basic Res Cardiol       Date:  1992 May-Jun       Impact factor: 17.165

2.  Peripheral sympatho-inhibitory cardiovascular effects of opioid peptides in anaesthetized rabbits.

Authors:  B Szabo; L Hedler; C Schurr; K Starke
Journal:  Br J Pharmacol       Date:  1988-07       Impact factor: 8.739

3.  Opioid peptides decrease noradrenaline release and blood pressure in the rabbit at peripheral receptors.

Authors:  B Szabo; L Hedler; H Ensinger; K Starke
Journal:  Naunyn Schmiedebergs Arch Pharmacol       Date:  1986-01       Impact factor: 3.000

4.  Effects of kappa opioid agonists alone and in combination with cocaine on heart rate and blood pressure in conscious squirrel monkeys.

Authors:  Charles W Schindler; Zofi Graczyk; Joanne P Gilman; S Stevens Negus; Jack Bergman; Nancy K Mello; Steven R Goldberg
Journal:  Eur J Pharmacol       Date:  2007-08-03       Impact factor: 4.432

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.